Of 33 new drugs approved by the Food and Drug Administration in 2001 and 2002, one-fifth of supporting clinical trials were not published in medical journals,

when they are, there are little changes that make the papers look more favorable towards the product,"

In 2004, Merck's blockbuster anti-inflammatory drug Vioxx was pulled from the market after killing an FDA-estimated 27,000 people. The drug doubled heart attack risk — a side effect that critics say was glossed over in the company's studies,

Another Merck blockbuster, the cholesterol-lowering drug Vytorin, has proven ineffective

GlaxoSmithKline's best-selling diabetes drug Avandia was allowed to remain on the market, but only with a label stating its apparent cardiovascular risks.

Italian FDA collects money from every drug company that sells drugs in Italy, pools that, and funds drug trials.

head-to-head drug comparisons that companies don't like to fund. And they have independent people peer-reviewing the trials. It's a great model